Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 1803
Gene Symbol: DPP4
DPP4
0.010 Biomarker group BEFREE Since DPP-4 inhibitors prevent the degradation of substance P involved in swallowing reflex, DPP-4 inhibitors were expected to prevent dysphagia and aspiration pneumonia. 31822955 2020
Entrez Id: 8406
Gene Symbol: SRPX
SRPX
0.010 Biomarker group BEFREE Multiple regression analysis showed that there was a significant association of the dysphagia severity (DRS and DOSS) with the percentile change of the narrowest OD (%dn OD) (r = 0.121, p < 0.01 and r = 0.020, p < 0.01, respectively). 31415467 2020
Entrez Id: 6554
Gene Symbol: SLC10A1
SLC10A1
0.010 Biomarker group BEFREE ΔNTCP >5% was seen five times for dysphagia and twice for the other toxicities. 31431381 2020
Entrez Id: 5411
Gene Symbol: PNN
PNN
0.010 Biomarker group BEFREE Multiple regression analysis showed that there was a significant association of the dysphagia severity (DRS and DOSS) with the percentile change of the narrowest OD (%dn OD) (r = 0.121, p < 0.01 and r = 0.020, p < 0.01, respectively). 31415467 2020
Entrez Id: 49
Gene Symbol: ACR
ACR
0.010 Biomarker group BEFREE ACR Appropriateness Criteria<sup>®</sup> Dysphagia. 31054737 2019
Entrez Id: 6737
Gene Symbol: TRIM21
TRIM21
0.010 Biomarker group BEFREE The incidence of mortality, subcutaneous emphysema, hoarseness and dysphagia in patients who were positive for both anti-MDA5 and anti-Ro52 antibodies was significantly higher than in patients positive for only anti-MDA5 antibodies. 30767866 2019
Entrez Id: 23495
Gene Symbol: TNFRSF13B
TNFRSF13B
0.010 Biomarker group BEFREE The factors that were associated with dysphagia were age > 74 years (OR 1.99), TACI (OR 5.82), mRS score ≥ 3 (OR 4.31), malnutrition (OR 3.27), and BMI ≥ 20 (OR 0.45). 31004231 2019
Entrez Id: 23451
Gene Symbol: SF3B1
SF3B1
0.010 GeneticVariation group BEFREE Dysphagia was identified with SCOPA-AUT question 1 (answer regularly) and was assessed with MDS-UPDRS Part-II, Item 2.3 (Chewing and Swallowing). 31344030 2019
Entrez Id: 8621
Gene Symbol: CDK13
CDK13
0.010 Biomarker group BEFREE Differential diagnosis and recommendations for clinical care of patients with CDK13-related disorder are also described, emphasizing baseline echocardiography, vigilance for feeding and swallowing difficulties, and regular developmental evaluation as key components of care. 30904094 2019
Entrez Id: 54790
Gene Symbol: TET2
TET2
0.010 GeneticVariation group BEFREE Dysphagia was identified with SCOPA-AUT question 1 (answer regularly) and was assessed with MDS-UPDRS Part-II, Item 2.3 (Chewing and Swallowing). 31344030 2019
Entrez Id: 10055
Gene Symbol: SAE1
SAE1
0.010 Biomarker group BEFREE Anti-SAE1 (OR 14.877, 95% CI 1.427-155.074), anti-SRP (OR 4.339, 95% CI 1.529-12.312) and anti-TIF1-γ (OR 2.790, 95% CI 1.578-4.935) were associated with dysphagia. 30863950 2019
Entrez Id: 4907
Gene Symbol: NT5E
NT5E
0.010 GeneticVariation group BEFREE Medically Unexplained Oropharyngeal Dysphagia at the University Hospital ENT Outpatient Clinic for Dysphagia: A Cross-Sectional Cohort Study. 29872993 2019
Entrez Id: 8518
Gene Symbol: ELP1
ELP1
0.010 GeneticVariation group BEFREE Dysphagia was the only symptom which differentiated patients with severe (14/16) or mild ELP (8/18) from patients without ELP (1/18). 31608788 2019
Entrez Id: 7195
Gene Symbol: TRNAG1
TRNAG1
0.010 Biomarker group BEFREE The reported dysphagia did not differ between those with a complete histological response (TRG 1) and those without any response at all (TRG 4) (P = 0.583). 30084992 2019
Entrez Id: 410
Gene Symbol: ARSA
ARSA
0.010 GeneticVariation group BEFREE Compared to controls, NUR-HV were younger (51.2 ± 16.8 years vs. 57.6 ± 15.2, p = 0.05), had a lower baseline BMI (28.2 ± 6.4 vs. 31.3 ± 5.4, p = 0.003) and ASA scores (p = 0.02), presented with higher GERSS (46 (28-60) vs. 35 (19-48), p = 0.02) and dysphagia scores (3 (1-5) vs. 2 (0-4), p = 0.02), were associated with LNF (77.7% vs. 54.6%, p = 0.02), and experienced more post-operative dysphagia (13.3% vs. 4.6%, p = 0.06). 31300909 2019
Entrez Id: 11014
Gene Symbol: KDELR2
KDELR2
0.010 GeneticVariation group BEFREE Dysphagia was the only symptom which differentiated patients with severe (14/16) or mild ELP (8/18) from patients without ELP (1/18). 31608788 2019
Entrez Id: 7531
Gene Symbol: YWHAE
YWHAE
0.010 GeneticVariation group BEFREE Dysphagia was identified with SCOPA-AUT question 1 (answer regularly) and was assessed with MDS-UPDRS Part-II, Item 2.3 (Chewing and Swallowing). 31344030 2019
Entrez Id: 2525
Gene Symbol: FUT3
FUT3
0.010 Biomarker group BEFREE Longer myotomy on the gastric side (>2.5 cm) ensures complete division of the LES with better outcomes in term of resolution of dysphagia but may be associated with higher postoperative GERD. 31012870 2019
Entrez Id: 2950
Gene Symbol: GSTP1
GSTP1
0.010 GeneticVariation group BEFREE In addition, the presence of G allele of GSTP1 was associated with a significantly lower risk of severe dysphagia (P = .0004). 30973677 2019
Entrez Id: 25859
Gene Symbol: PART1
PART1
0.010 Biomarker group BEFREE This paper is a continuation of PART 1 and it provides detailed computed tomography (CT)-based delineation guidelines for FSUs, which presumably are also at risk of radiation-induced dysphagia. 30551889 2019
Entrez Id: 5048
Gene Symbol: PAFAH1B1
PAFAH1B1
0.010 GeneticVariation group BEFREE Dysphagia was identified with SCOPA-AUT question 1 (answer regularly) and was assessed with MDS-UPDRS Part-II, Item 2.3 (Chewing and Swallowing). 31344030 2019
Entrez Id: 1437
Gene Symbol: CSF2
CSF2
0.010 Biomarker group BEFREE The most consistent indications for surgical intervention in early hydrocephalus were CSF leak from the back (92%), progressive ventricular enlargement (89%), and brainstem symptoms, including apnea/bradycardia (81%), stridor (81%), and dysphagia (81%). 31470398 2019
Entrez Id: 3918
Gene Symbol: LAMC2
LAMC2
0.010 Biomarker group BEFREE The most consistent indications for surgical intervention in early hydrocephalus were CSF leak from the back (92%), progressive ventricular enlargement (89%), and brainstem symptoms, including apnea/bradycardia (81%), stridor (81%), and dysphagia (81%). 31470398 2019
Entrez Id: 90226
Gene Symbol: UCN2
UCN2
0.010 Biomarker group BEFREE Anti-SAE1 (OR 14.877, 95% CI 1.427-155.074), anti-SRP (OR 4.339, 95% CI 1.529-12.312) and anti-TIF1-γ (OR 2.790, 95% CI 1.578-4.935) were associated with dysphagia. 30863950 2019
Entrez Id: 57380
Gene Symbol: MRS2
MRS2
0.010 Biomarker group BEFREE The poor outcome was defined as a condition that includes the mRS ≥2 and/or dysphagia at one year after onset. 30875528 2019